CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 134 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2017. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $56,000 | -43.4% | 23,846 | -30.9% | 0.00% | – |
| Q4 2017 | $99,000 | +15.1% | 34,525 | +15.8% | 0.00% | – |
| Q3 2017 | $86,000 | +16.2% | 29,805 | 0.0% | 0.00% | – |
| Q2 2017 | $74,000 | -19.6% | 29,805 | +17.6% | 0.00% | – |
| Q1 2017 | $92,000 | -22.0% | 25,351 | -23.9% | 0.00% | – |
| Q4 2016 | $118,000 | +22.9% | 33,302 | +35.1% | 0.00% | – |
| Q3 2016 | $96,000 | -11.1% | 24,657 | 0.0% | 0.00% | – |
| Q2 2016 | $108,000 | +17.4% | 24,657 | 0.0% | 0.00% | – |
| Q1 2016 | $92,000 | -73.8% | 24,657 | +11.0% | 0.00% | – |
| Q4 2015 | $351,000 | +80.0% | 22,214 | +21.9% | 0.00% | – |
| Q3 2015 | $195,000 | -56.8% | 18,230 | 0.0% | 0.00% | -100.0% |
| Q2 2015 | $451,000 | -5.5% | 18,230 | +7.2% | 0.00% | 0.0% |
| Q1 2015 | $477,000 | +84.9% | 17,012 | +23.1% | 0.00% | – |
| Q4 2014 | $258,000 | +34.4% | 13,819 | -3.5% | 0.00% | – |
| Q3 2014 | $192,000 | – | 14,320 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,000 | $3,096,000 | 100.00% |
| TSP Capital Management Group, LLC | 698,674 | $1,549,000 | 0.79% |
| Meditor Group Ltd | 6,312,700 | $2,847,000 | 0.61% |
| Telemetry Investments, L.L.C. | 186,200 | $84,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 1,270,500 | $573,000 | 0.03% |
| Benchmark Capital Advisors | 53,400 | $24,000 | 0.02% |
| BOENNING & SCATTERGOOD, INC. | 80,150 | $36,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 80,000 | $36,000 | 0.01% |
| Centiva Capital, LP | 121,720 | $55,000 | 0.01% |
| Overbrook Management Corp | 48,611 | $22,000 | 0.00% |